Login to Your Account



ICAAC Roundup


Monday, September 16, 2013
• Gilead Sciences Inc., of Foster City, Calif., disclosed 48-week results from a Phase II study (Study 102) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription